uBriGene to Attend Meeting on the Mesa 2026

uBriGene Biosciences will participate in Cell & Gene Meeting on the Mesa, October 5–7 in Phoenix, bringing its integrated cell and gene therapy technology and development capabilities to conversations with biotechnology and pharmaceutical innovators.

As advanced therapy programs progress toward clinical development and commercialization, developers are navigating increasingly complex challenges across cell engineering, gene delivery, gene editing, process development, analytics, and GMP manufacturing. uBriGene addresses these needs through an integrated platform designed to help bridge ATMP concepts to commercialization.

uBriGene’s capabilities span cell therapy, gene therapy, gene editing, iPSC technologies, RNA-LNP, viral vectors, and emerging in vivo approaches, supported by process development, analytical development, and GMP manufacturing capabilities.

At Meeting on the Mesa, the uBriGene team will connect with cell and gene therapy developers, biotech and pharmaceutical companies, investors, and potential strategic partners to exchange perspectives on emerging technologies, development challenges, and opportunities to accelerate advanced therapy programs.

With a mission to accelerate ATMP development and manufacturing from concept to commercialization, uBriGene continues to build collaborative partnerships across the cell and gene therapy ecosystem.

Meet with uBriGene in Phoenix to discuss your cell and gene therapy program, development or manufacturing needs, or potential collaboration opportunities.

Cell & Gene Meeting on the Mesa 2026

October 5–7, 2026

Phoenix, Arizona

Interested in connecting with uBriGene?

Contact us to schedule a one-on-one meeting to discuss your project needs and partnership opportunities.